NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc (NASDAQ: NTHI) reported significant improvement in a critically ill 3-year-old boy with an aggressive brain tumor after receiving NEO100
Covered in this story
Call it yourself
No calls on $NEO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Neogenomics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.